PTGX vs VLPNY
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PTGX · Protagonist Therapeutics$132.04 ▼ 2.38%
VLPNY · VOESTALPINE AG UNSP ADR EACH REPR 1/5 ORD EUR0.00$9.00 ▼ 3.85%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PTGX +58.6%
- VLPNY +31.7%
Head to head
| Metric | PTGX | VLPNY |
|---|---|---|
| Price | $132.04 | $9.00 |
| Change today | ▼ 2.38% | ▼ 3.85% |
| Market cap | $8.54B | $8.55B |
| Return, 3 months | -12.0% | -13.9% |
| Return, year to date | +51.2% | +7.7% |
| Return, 1 year | +66.0% | +31.7% |
| P/E (TTM) | 27.9 | 13.0 |
| P/B | 7.9 | 0.9 |
| P/E percentile vs own 5y | 98th | – |
| Dividend yield | – | 1.91% |
| Revenue growth (YoY, latest qtr) | +3,749.2% | – |
| Net profit growth (YoY) | +568.3% | – |
| Gross margin | – | – |
| Operating margin | 20.7% | – |
| Net margin | 29.4% | – |
| Return on equity | 11.0% | – |
| Analyst target vs. price | +32.2% | – |
| Analyst buy share | 100% | – |
| RSI (14) | 39 | 33 |
| 30-day volatility | 37.8% | 32.9% |
| Max drawdown, 1 year | -18.8% | -28.2% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | – |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- VLPNY is the largest of the group by market value.
- PTGX has returned the most over the past year.
- VLPNY carries the lowest trailing P/E.
- VLPNY has been the calmest stock over the last 30 days.